Chromadex Corp
Change company Symbol lookup
Select an option...
CDXC Chromadex Corp
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
Go

Health Care : Life Sciences Tools & Services | Small Cap Growth
Company profile

ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.

Closing Price
$4.35
Day's Change
-0.26 (-5.64%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.59
Day's Low
4.27
Volume
(Light)
Volume:
256,711

10-day average volume:
378,686
256,711

Display:

Providers:

UpdateCancel
6 providers
November 03, 2021
ChromaDex Corporation Reports Third Quarter 2021 Financial Results

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2021. Third Quarter 2021 and Recent Highlights Total net sales were $17.3 million, up 22% from the prior year quarter. Tru Niagen(R) net sales were $14.8...(BusinessWire)

October 18, 2021
ChromaDex Shares Findings from First Clinical Study on Nicotinamide Riboside (NR) in Children, Highlighting Improvements for Prematurely Aging Patients with Ataxia-Telangiectasia (AT)

ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a first-of-its-kind clinical study published in the peer-reviewed journal, Movement Disorders, conducted by Michel A.A.P. Willemsen MD, PhD of Radboud University Medical Center...(BusinessWire)

October 13, 2021
ChromaDex to Report Third Quarter 2021 Financial Results on Wednesday, Nov. 3, 2021

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wednesday, Nov. 3, 2021 at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sep. 30, 2021. The financial results will be reported in a press...(BusinessWire)

October 01, 2021
ChromaDex Comments on Jury Award Against Elysium Health and Reiterates Plans for Growth

--New partnership with Sinopharm Xingsha and recent partnerships with Walmart, H&H Group, and Ro to support next phase of growth ChromaDex Corp. (NASDAQ:CDXC) today announced that a jury in the United States District Court for the Central...(BusinessWire)

September 29, 2021
ChromaDex Partners with Sinopharm Xingsha for Cross-Border Sales of Tru Niagen(R) into Mainland China

ChromaDex Corp. (NASDAQ: CDXC) announced today a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. ("Sinopharm Xingsha") to conduct cross-border sales of Tru Niagen(R) in mainland China. Sinopharm Xingsha is a subsidiary of...(BusinessWire)

September 20, 2021
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP(TM))

ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen(R) (patented nicotinamide riboside, or "NR") in various health outcomes...(BusinessWire)

September 15, 2021
ChromaDex Continues to Defend Strong Intellectual Property Portfolio and Plans to Appeal Judge's Ruling in Patent Infringement Lawsuit

ChromaDex Corp. (NASDAQ:CDXC) issued the following statement: ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against Elysium Health, Inc...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.